Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Global Partners Reports Third-Quarter 2025 Financial Results
08:00am, Friday, 07'th Nov 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global” or the “Partnership”) today reported financial results for the third quarter ended September 30, 2025. CEO Commentary
Medicare to Cover GLP-1 Drugs for as Little as $50 a Month
05:04pm, Thursday, 06'th Nov 2025
Seniors could soon pay just $50 a month for Ozempic and other drugs used for weight loss under a new Trump plan to cut prescription costs.
Omada Health Announces GLP-1 Prescribing Capability to Support Growing Member Population
04:10pm, Thursday, 06'th Nov 2025
SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit health care provider, today announced the planned launch of its prescribing capability. A
Omada Health Reports Third Quarter 2025 Results
04:10pm, Thursday, 06'th Nov 2025
Revenue of $ 68 million, up 49% ; 53% Member Growth Significant Reduction in Net Loss and First Quarter of Positive Adjusted EBITDA Announces New GLP-1 Prescribing Offering SAN FRANCISCO, Nov. 06, 202
Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows
04:05pm, Thursday, 06'th Nov 2025
Virtual care company Omada Health said it will start prescribing GLP-1s and other obesity drugs and help patients manage those medications. The announcement expands the offerings under the company's w
Eli Lilly and Novo Nordisk lower GLP-1 drug costs in new deal with Trump.
03:30pm, Thursday, 06'th Nov 2025
About Yahoo Finance: Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage
Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost
01:01pm, Thursday, 06'th Nov 2025
Novo Nordisk has agreed with the U.S.
2 Reasons I'm Keeping My Eye on Eli Lilly Stock Right Now
06:09pm, Wednesday, 05'th Nov 2025
Eli Lilly is dominating the large and rapidly growing incretin analog market in the U.S. with its GLP-1 drug, tirzepatide. Its investigational oral GLP-1 drug, orforglipron, could significantly expand
Novo Nordisk Is Seeing Slowing Demand for GLP-1s Wegovy and Ozempic
12:00pm, Wednesday, 05'th Nov 2025
U.S.-listed shares of Novo Nordisk (NVO) fell after the drugmaker scaled back its outlook, citing disappointing demand for its GLP-1 weight loss and diabetes drugs as competition in the sector increas
Novo Nordisk Slides as GLP-1 Fatigue and Pricing Risks Cloud 2025 Outlook
11:54am, Wednesday, 05'th Nov 2025
Shares of Novo Nordisk (NVO) slipped about 1% on Wednesday morning after the company issued a cautious outlook, even though third-quarter revenue exceeded estim
Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles
11:31am, Wednesday, 05'th Nov 2025
NVO's Q3 profit and revenues miss expectations as Wegovy and Ozempic growth slows amid U.S. compounding and pricing headwinds.
Hims & Hers: GLP-1 Partnership Could Unlock Value
07:02am, Wednesday, 05'th Nov 2025
Hims & Hers Health reported strong 3Q25 revenue growth of 49% YoY, despite a GAAP EPS miss and shares falling post-earnings. HIMS is expanding its offerings, including testosterone and potential at-ho
Market Today: AMD beats, U.S. Steel plans, GLP-1 deal, Bitcoin drops
05:34pm, Tuesday, 04'th Nov 2025
Guru Stock PicksMatthews Japan Fund has made the following transactions:Reduce in TSE:2802 by 44.5%Sold out in TSE:3774Add in TSE:6503 by 77.82%New position in
Omada Health to Present Real-World Evidence at ObesityWeek 2025 Demonstrating Enhanced Outcomes for Current and Former GLP-1 Users
12:00pm, Tuesday, 04'th Nov 2025
SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, announced it will present two posters at ObesityWeek 2025 highlighting the
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
